Josep Quer Sivila I am a senior researcher at VHIR, specializing in Virology. Since 1989, I have focused my studies on research regarding the infection by the Hepatitis C virus (HCV), with a special emphasis on viral diversity. In 1992, I participated in the first description of the quasispecies nature of HCV. Since 2010, our research has been centred on the use of next-generation sequencing (NGS) platforms to study the diversity of viral genomes, especially viral hepatitis (A, B, C, D, and E). We have successfully patented and implemented into routine diagnosis a method for subtype classification and another for reporting resistances to antiviral treatments against HCV. The complete sequencing of SARS-CoV-2 in March 2020 has allowed us to monitor the tracking variations in defective genomes in the variants that have dominated each wave of SARS-CoV-2. Currently, we are developing bioinformatic pipelines for metagenomic studies. Instituciones de las que forman parte Investigador/a principal Enfermedades Hepáticas Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Email Josep Quer Sivila LinkedIn Twitter Orcid Email Instituciones de las que forman parte Investigador/a principal Enfermedades Hepáticas Vall Hebron Institut de Recerca I am a senior researcher at VHIR, specializing in Virology. Since 1989, I have focused my studies on research regarding the infection by the Hepatitis C virus (HCV), with a special emphasis on viral diversity. In 1992, I participated in the first description of the quasispecies nature of HCV. Since 2010, our research has been centred on the use of next-generation sequencing (NGS) platforms to study the diversity of viral genomes, especially viral hepatitis (A, B, C, D, and E). We have successfully patented and implemented into routine diagnosis a method for subtype classification and another for reporting resistances to antiviral treatments against HCV. The complete sequencing of SARS-CoV-2 in March 2020 has allowed us to monitor the tracking variations in defective genomes in the variants that have dominated each wave of SARS-CoV-2. Currently, we are developing bioinformatic pipelines for metagenomic studies.
Senior Researcher at Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus from 2021 (indefinite contract). Associate Professor at the Biochemistry and Molecular Department of the UAB from 2021 to present (3933001435 Y0LOU0146). Accredited researcher at CIBERehd (2010-prest). Accredited as Professor (Catedrático) from AQU (Generalitat de Catalunya) from 2023. Academic background: Bachelor in Biology from UB (1981-86). PhD in Biology from UAB (1994) with extraordinary award. Postdoctoral stay in the University of California at San Diego USA (1994-96). Member of Ciberehd since 2007-act. Associate Professor (AP) of Immunology, UB (1988-89); AP Medicine, UAB (2003-18); AP of Biochemistry and Molecular Biology, UAB (2021-pres.). General Coordinator Master in "Translational Biomedical Research" VHIR-UAB (2020-pres.). Professor and coordinator of Module 1 Master in "Translational Biomedical Research" VHIR-UAB since 2014-pres. Scientific and professional activities: Projects: Since 2016, he has led 10 overlapping competitive financed projects, serving as the Principal Investigator (PI) in eight national projects and as the co-IP of the local-node in two European Union projects. Thesis: 6 PhD thesis directed, and 3 under development. Papers and reviews: 154 papers; 8 book chapters & 1 book published in 2023. Meetings participation: 220, 66 of them as invited speaker. Other merits: Member Coordinator Committee “Strategic Plan for Tackling hepatitis C (PEAHC) Spanish Ministry of Health; Treasurer Spanish Society of Virology (SEV) (2009-pres.); Member of scientific societies (ESV;AEEH;SCB) and of Alliance for the Elimination of Hepatitis in Spain (AEHVE). Organizing Committee of International Symposium Fundación Ramón Areces (2013); and SEV National Meetings (2013-2015-2017-2019-2022). Impacts printed, digital, radio and TV. NGS-2010: 32 impacts; HCV-2015: 69 impacts; SARS-CoV-2 – 2020-23: 90 impacts. Awards: Ciudad de Barcelona (1996); Best ideas Diario Medico (2015); Premi Ciència i Tecnologia Diari Regió7-Prensa Ibérica (2020). Metrics: h-index:41 (scholar), 35 (WoS), 37 (Scopus); i10-index: 116; Citations (WoS): 8371; Views: >40000. ORCID: 0000-0003-0014-084X // WOS ResearcherID A-6741-2012 // SCOPUS ID: 7004592398 Social media: Linkedin: Josep Quer Twitter (X): @JosepQuerSivila / @VirusLabQ (Virus Lab by Dr. Josep Quer) / @HepatitisSEV
Proyectos FPU 2021 IP: Josep Quer Sivila Colaboradores: Sergi Colomer Castell Entidad financiadora: Ministerio de Universidades Financiación: 73389.26 Referencia: FPU21/04150 Duración: 16/12/2022 - 15/05/2025 Malalties hepàtiques IP: Joan Genescà Ferrer Colaboradores: Beatriz Minguez Rosique, Sergi Colomer Castell, Elena Vargas Accarino, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Maria Buti Ferret, Montserrat Gomez Perez, Judit Romero Vico, Josep Quer Sivila, Adriana Palom Agusti, Juan Manuel Pericàs Pulido, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Daniel Martinez Vazquez, Laura Puente Ramo, Isabel Campos Varela, María Bermúdez Ramos, Juan Ignacio Esteban Mur, Ester Palacio Gutierrez, Susana Anton Calvo, Monica Higuera Urbano, Meritxell Ventura Cots, Ares Aurora Villagrasa Vilella, Emma Bigas Alsina, Carolina Campos Martinez, Macarena Simon-Talero Horga, David Tabernero Caellas, Mònica Pons Delgado, Marcella Salzano Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca Financiación: 60000 Referencia: 2021 SGR 00462 Duración: 01/01/2022 - 30/06/2025 Enhancing Whole Genome Sequencing (WGS) and/or Reverse Transription Polymerase Chain Reaction (RT-PCR) national infrastructures and capacities to respond to the COVID-19 pandemic in the European Union and European Economic Area IP: Josep Quer Sivila Colaboradores: Narcís Saubí Roca Entidad financiadora: EUROPEAN COMMISSION Financiación: 136643.73 Referencia: WGS-RTPCR_ECDC2021 Duración: 03/09/2021 - 30/09/2022 QUASISPECIES OF SARS-COV-2 SPIKE GENE OF VOC VARIANTS FOR VACCINE IMPROVEMENTS IP: Josep Quer Sivila Colaboradores: - Entidad financiadora: GILEAD SCIENCES SLU Financiación: 35477.2 Referencia: GLD21-00006 Duración: 01/01/2022 - 31/12/2023 Paginación Primera página « Página anterior ‹ Página 1 Página actual 2 Página 3 Página 4 Página 5 … Siguiente página › Última página »